(Q51959493)

19 April 2018

title

Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease? (English)

1 reference

19 April 2018

1 reference

2

1 reference

19 April 2018

Kaj Blennow

series ordinal

3

object named as

K Blennow

1 reference

19 April 2018

4

E Londos

1 reference

19 April 2018

Lennart Minthon

series ordinal

5

object named as

L Minthon

1 reference

19 April 2018

author name string

A K Wallin

series ordinal

1

1 reference

19 April 2018

language of work or name

English

0 references

publication date

1 June 2009

1 reference

19 April 2018

International Journal of Geriatric Psychiatry

published in

1 reference

19 April 2018

volume

24

1 reference

19 April 2018

issue

6

1 reference

19 April 2018

page(s)

638-647

1 reference

19 April 2018

Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease

cites work

1 reference

The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease.

21 January 2018

1 reference

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations

21 January 2018

1 reference

A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration.

21 January 2018

1 reference

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

21 January 2018

1 reference

Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients

21 January 2018

1 reference

7 January 2021

Alzheimer's disease: choline acetyltransferase activity in brain tissue from clinical and pathological subgroups

1 reference

7 January 2021

Cholinesterase inhibitors for Alzheimer's disease

1 reference

7 January 2021

Longitudinal stability of CSF biomarkers in Alzheimer's disease.

1 reference

7 January 2021

Neuropathological stageing of Alzheimer-related changes

1 reference

7 January 2021

Drug treatment effects on disease progression.

1 reference

7 January 2021

Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease

1 reference

7 January 2021

Sustained cognitive improvement following treatment of Alzheimer's disease with donepezil.

1 reference

7 January 2021

Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression

1 reference

7 January 2021

1 reference

7 January 2021

The cholinergic hypothesis of Alzheimer's disease: a review of progress

1 reference

7 January 2021

Indicators of neuroprotection with galantamine

1 reference

7 January 2021

Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: a meta-analysis.

1 reference

7 January 2021

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

1 reference

7 January 2021

Regional cerebral blood flow patterns and response to donepezil treatment in patients with Alzheimer's disease

1 reference

7 January 2021

Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?

1 reference

7 January 2021

Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications.

1 reference

7 January 2021

Disease stage in Alzheimer disease and treatment effects of rivastigmine

1 reference

7 January 2021

Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living

1 reference

7 January 2021

Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.

1 reference

7 January 2021

Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease.

1 reference

7 January 2021

What constitutes clinical evidence for neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors?

1 reference

7 January 2021

Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

1 reference

7 January 2021

Clinical predictors of response to Acetyl Cholinesterase Inhibitors: experience from routine clinical use in Newcastle

1 reference

7 January 2021

Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.

1 reference

7 January 2021

Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease

1 reference

7 January 2021

Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease

1 reference

7 January 2021

Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months

1 reference

7 January 2021

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

1 reference

7 January 2021

Effectiveness of acetylcholinesterase inhibitors: diagnosis and severity as predictors of response in routine practice

1 reference

7 January 2021

Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients.

1 reference

7 January 2021

Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.

1 reference

7 January 2021

Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy

1 reference

7 January 2021

Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.

1 reference

7 January 2021

Identifiers

DOI

10.1002/GPS.2195

1 reference

19 April 2018

PubMed ID

19123199

1 reference

19 April 2018